IL-33 Suppresses the Progression of Atherosclerosis via the ERK1/2-IRF1-VCAM-1 Pathway.

Qian, Zhang; Shaofang, Feng; Chen, Chen; Chunhua, Shi; Nan, Wang; Chao, Liu

Qian, Zhang; Shaofang, Feng; Chen, Chen; Chunhua, Shi; Nan, Wang; Chao, Liu.

Afiliación

Qian Z; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, 68 Changle Rd, Nanjing, 210006, Jiangsu, China.
Shaofang F; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, Jiangsu, China.
Chen C; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, 68 Changle Rd, Nanjing, 210006, Jiangsu, China.
Chunhua S; Medical Department, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu, China.
Nan W; Jinling Hospital, Medical School of Nanjing University, 22 Hankou Rd, Nanjing, 210093, Jiangsu, China. qhylqyjk@163.com.
Chao L; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, 68 Changle Rd, Nanjing, 210006, Jiangsu, China. njdyyyzq@foxmail.com.

Cardiovasc Drugs Ther ; 2023 Nov 14.

Article en En | MEDLINE | ID: mdl-37957490

Palabras clave

Anti-inflammatory; Atherosclerosis; IL-33; TNF-α; VCAM-1

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cardiovasc Drugs Ther Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google